budesonide / Generic mfg. - LARVOL DELTA

Efficacy and Safety of a Targeted-release Formulation of Budesonide (HR19042 Capsules) in Patients With Primary IgA Nephropathy: A Randomized, Double-blind, Multicenter, Placebo-controlled Phase 2/3 Trial (ISN-WCN 2026) - No abstract available

Clinical • Late-breaking abstract • P2/3 data • Glomerulonephritis • IgA Nephropathy • Renal Disease

Collagenous Colitis in a Young Adult: A Case Report. (PubMed, Cureus) - "Budesonide remains the first-line treatment and achieves high remission rates. Collagenous colitis should be considered in the differential diagnosis of chronic watery diarrhea, even in young adults. Furthermore, early biopsy and appropriate therapy are crucial for symptom control and improved quality of life."

Journal • Gastroenterology • Gastrointestinal Disorder • Immunology

INCIDENCE, RISK FACTORS AND OUTCOMES OF AVASCULAR NECROSIS IN ALLOGENEIC STEM CELL TRANSPLANT RECIPIENTS DEVELOPING GRAFT-VERSUS-HOST DISEASE (EBMT 2026) - "All patients had hip involvement with median ARCO stage II; 4 had shoulder and 1 had wrist involvement(median number of joints involved: 2,range:1-4).Twelve AVN patients required vitamin D supplementation at diagnosis of AVN, and 13 received bisphosphonates(alendronate:11, zoledronate:2)...AVN cases received higher starting dose of systemic steroids for acute GVHD(median:2.19 vs 1.19 mg/kg prednisolone equivalents, p=0.016), but there were no differences in steroid therapy duration, steroid-refractoriness, or use of maintenance prednisolone and oral budesonide... Symptomatic AVN incidence among ASCT recipients who developed GVHD was 6.4%, with 57% requiring surgery. Higher pre-ASCT steroid exposure, higher initial steroid dose for acute GVHD, higher CD3+ cell dose, and pre-ASCT vitamin D deficiency were potentially modifiable risk factors for AVN."

Clinical • Acute Graft versus Host Disease • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Hodgkin Lymphoma • Immunology • Lymphoma • Orthopedics • Transplantation

DECEASED DONOR BONE MARROW TRANSPLANT: FIRST EVER HUMAN CASE REPORT OF SUCCESSFUL ENGRAFTMENT AFTER INFUSION OF A CRYOPRESERVED DECEASED DONOR BONE MARROW IN A PATIENT WITH AML (EBMT 2026) - "Prior to transplant the patient received fludarabine 30 mg/m2 (Day -6 to Day -2), melphalan 140 mg/m2 ( Day -6) and TBI 2Gy in one fraction, as part of reduced intensity conditioning regimen...Graft-versus-host disease (GVHD) prophylaxis consisted of tacrolimus, mycophenolate mofetil and two doses of post-transplant cyclophosphamide (PTCy) at a dose of 50 mg/kg administered on Days +3 and +4...The acute GVHD is being treated with budesonide 3 mg by mouth daily and tacrolimus 2.5 mg twice daily, and her GVHD was well controlled... The successful engraftment in this case demonstrates the potential of cryopreserved HPC marrow from mismatched deceased organ donors as a viable option for HCT. HCT with a MMUD cryopreserved HPC marrow from a deceased organ donor can play a significant role in expanding access to HCT for patients who have unmet needs, and it can be made available "on demand". Clinical studies are currently being conducted to further evaluate the safety..."

Case report • Clinical • Acute Graft versus Host Disease • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Transplantation • CD34

Systemic corticosteroid use in IBD patients receiving advanced therapies: real-world data from IBDREAM (ECCO-IBD 2026) - "Secondary outcomes included budesonide use during advanced therapies...In both CD and UC, vedolizumab was associated with relatively high corticosteroid use throughout both the induction and maintenance phases. In UC patients, high corticosteroid use was also observed during the induction phase of infliximab...The acute nature of UC flares may also contribute to the higher corticosteroid use observed in UC compared to CD. In CD, therapies typically prescribed in later lines of treatment were associated with increased corticosteroid use, possibly due to reduced efficacy of advanced therapies in refractory patients."

Clinical • Metastases • Real-world • Real-world evidence • Crohn's disease • Inflammatory Bowel Disease • Ulcerative Colitis • IL12A

Efficacy and safety of budesonide for the treatment of IgA nephropathy: a systematic review and meta-analysis. (PubMed, Int Urol Nephrol) - "Current evidence indicates that TRF-budesonide improves kidney function and reduces proteinuria in adults with IgAN, but conclusions are tempered by limited RCT data, heterogeneity, short follow-up, and sparse histologic end points. Larger, longer randomized trials with standardized outcomes are needed to confirm long-term benefit and safety."

Journal • Retrospective data • Chronic Kidney Disease • Glomerulonephritis • IgA Nephropathy • Nephrology • Renal Disease

Randomized Controlled Pilot Trial of Budesonide Administration with Surfactant in Very Low Birth Weight Baby with Perinatal Ureaplasma Urealyticum Infection(BABY-UU pilot trial) (ChiCTR) - P4 | N=252 | Not yet recruiting | Sponsor: Guangzhou Women and Children's Medical Center,Guangzhou Medical University; Guangzhou Women and Children's Medical Center,Guangzhou Medical University

New P4 trial • Infectious Disease

The influence of CD27-CD21+ B cells and IgA plasma cell changes in patients with IgA nephropathy on the prognosis of treatment with Nefecon (ChiCTR) - P4 | N=96 | Not yet recruiting | Sponsor: Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University; Shenzhen Second People's Hospital, The First Affiliated Hospi

New P4 trial • Glomerulonephritis • IgA Nephropathy • Renal Disease

Metabolic Checkpoints in IgA Nephropathy: From Pathogenesis to Precision Medicine. (PubMed, Drugs) - "Contemporary management of IgAN combines causal therapy against pathogenic galactose-deficient immunoglobulin A1, including enteric budesonide with symptom-oriented interventions via renin-angiotensin system inhibitors to mitigate hypertension, glomerular hyperfiltration, proteinuria, and cardiovascular sequelae...Interventions targeting metabolic checkpoints, including sodium-glucose cotransporter 2 inhibitors, mechanistic target of rapamycin inhibitors and peroxisome proliferator-activated receptor-γ agonists demonstrate promising renoprotective effects in IgAN preclinical models and early-phase trials, heralding the era of dual metabolic-immune precision therapeutics...Future research should integrate multi-omics and single-cell analysis to delineate metabolic heterogeneity and develop renal-targeted nanodelivery systems for endotype-based precision medicine. This paradigm shift will guide IgAN mechanism exploration and management, transitioning from conventional..."

Journal • Review • Cardiovascular • Fibrosis • Glomerulonephritis • Hypertension • IgA Nephropathy • Immunology • Metabolic Disorders • Renal Disease • HIF1A • IDO1

IgA Nephropathy in Adults: A Review. (PubMed, JAMA) - "Based on the Kidney Disease: Improving Global Outcomes 2025 clinical practice guideline for the management of IgAN, treatment for patients with proteinuria greater than 0.5 g per day includes behavioral modifications (eg, dietary sodium <2 g/d, smoking cessation, weight control, exercise), antihypertensive medications for goal blood pressure less than 120/70 mm Hg, and therapies to reduce the formation of IgA-containing immune complexes (eg, targeted-release budesonide), decrease glomerular injury (eg, systemic glucocorticoids, iptacopan), and manage existing IgAN-induced nephron loss (eg, renin-angiotensin system inhibitor or dual endothelin angiotensin receptor antagonist [eg, sparsentan] alone or in combination with a sodium-glucose cotransporter 2 inhibitor). Patients with suspected IgAN and proteinuria greater than or equal to 0.5 g per day should undergo kidney biopsy to confirm the diagnosis. Treatment of IgAN includes behavioral modifications, blood pressure..."

Journal • Ankylosing Spondylitis • Celiac Disease • Chronic Kidney Disease • Fibrosis • Gastroenterology • Gastrointestinal Disorder • Glomerulonephritis • IgA Nephropathy • Immunology • Infectious Disease • Inflammation • Inflammatory Arthritis • Inflammatory Bowel Disease • Lupus • Lupus Nephritis • Nephrology • Renal Disease • Seronegative Spondyloarthropathies • Spondylarthritis • Tobacco Cessation • Vasculitis

Early Intratracheal Budesonide to Reduce Bronchopulmonary Dysplasia in Extremely Preterm Infants. (PubMed, JAMA) - No abstract available

Journal • Bronchopulmonary Dysplasia • Pulmonary Disease • Respiratory Diseases

Early Intratracheal Budesonide to Reduce Bronchopulmonary Dysplasia in Extremely Preterm Infants. (PubMed, JAMA) - No abstract available

Journal • Bronchopulmonary Dysplasia • Pulmonary Disease • Respiratory Diseases

Early Intratracheal Budesonide to Reduce Bronchopulmonary Dysplasia in Extremely Preterm Infants-Reply. (PubMed, JAMA) - No abstract available

Journal • Bronchopulmonary Dysplasia • Pulmonary Disease • Respiratory Diseases

Oral Local Budesonide Treatment Ameliorates Immune Activation and Colonic Sensitivity in a Spontaneous Model for Disorders of Gut-Brain Interaction. (PubMed, Neurogastroenterol Motil) - "Together, these results demonstrate that a local anti-inflammatory treatment improved intestinal permeability and visceral hypersensitivity in a preclinical, spontaneous model of DGBI. Moreover, it supports a role for intestinal inflammation in the intestinal barrier defect and symptoms, further paving the way for additional evaluation of anti-inflammatory treatments, including budesonide, in DGBI."

Journal • CNS Disorders • Diabetes • Dyspepsia • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Metabolic Disorders

Microscopic Colitis: Evidence-Based Guide to Diagnosis and Management. (PubMed, Annu Rev Med) - "However, relapse rates are high, necessitating alternative treatment strategies. Long-term maintenance strategies include low-dose budesonide, bile salt binders, antidiarrheals, and advanced therapies for refractory cases."

Journal • Review • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease

Real-world experience of budesonide orodispersible tablets in pediatric eosinophilic esophagitis. (PubMed, J Pediatr Gastroenterol Nutr) - "After a median follow-up of 12.5 months (6.25-21 IQR), 11/17 (65%) patients were still on BOT treatment, and 9/11 (82%) were in clinical remission. No adverse events were reported."

Journal • Real-world evidence • Eosinophilic Esophagitis • Gastrointestinal Disorder • Immunology • Inflammation • Pediatrics

STEROID-RELATED ADVERSE EVENTS OF CHRONIC BUDESONIDE USE IN PATIENTS AGE 60 AND OLDER WITH INFLAMMATORY BOWEL DISEASE AND MICROSCOPIC COLITIS (CCCongress 2026) - "Rates of adverse events were compared to mesalamine and prednisone users. More studies on long term safety of budesonide are needed. It is important to adopt steroid-sparing strategies to long-term budesonide users."

Adverse events • Clinical • Cataract • CNS Disorders • Crohn's disease • Diabetes • Gastroenterology • Gastrointestinal Disorder • Glaucoma • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Musculoskeletal Diseases • Ophthalmology • Orthopedics • Osteoporosis • Rheumatology • Ulcerative Colitis

Delayed-release budesonide combined with cyclophosphamide in a patient with IgA nephropathy with eGFR < 30 mL/min/1.73 m²: A case report. (PubMed, Medicine (Baltimore)) - "This case suggests that delayed-release budesonide in combination with cyclophosphamide on the basis of supportive therapy is effective in treating adult IgA nephropathy patient with eGFR < 30 mL/min/1.73 m2. This approach warrants further investigation in larger prospective studies."

Journal • Chronic Kidney Disease • Glomerulonephritis • IgA Nephropathy • Nephrology • Otorhinolaryngology • Renal Disease

Kappa-Restricted IgA Nephropathy Treated Successfully With Targeted-Release Budesonide. (PubMed, Kidney Int Rep) - No abstract available

Journal • Glomerulonephritis • IgA Nephropathy • Renal Disease

Steroid-sparing strategies for managing immune-related adverse events. (PubMed, J Immunother Cancer) - "Thus, there is a critical need for steroid-sparing treatment approaches for irAEs.In this article, we review the literature for alternative therapeutic approaches for irAEs, which include targeted delivery (alternate routes of administration) of steroids (eg, budesonide) as well as systemic non-steroidal strategies using other mechanisms of action, such as integrin/cytokine blockade, antibody depletion, disease-modifying antirheumatic drugs and fecal microbiota transplant, among others...These approaches are being increasingly used as primary and secondary prophylaxis in patients at high risk of irAEs. Importantly, these strategies may mitigate steroid-associated toxicities, preserve antitumor immune responses and allow continuation of ICI after development of irAEs, hence enabling the full potential of ICI against cancer."

Adverse events • Journal • Review • Gastroenterology • Gastrointestinal Disorder • Immunology • Oncology • Transplantation

A Multi-center Open Label Prospective Study on Early Initiation of Targeted-release Formulation of Budesonide in Patients With Primary IgA Nephropathy (clinicaltrials.gov) - P=N/A | N=200 | Recruiting | Sponsor: Sichuan Provincial People's Hospital | Not yet recruiting ➔ Recruiting

Enrollment open • Glomerulonephritis • IgA Nephropathy • Renal Disease

Chronic Watery Diarrhea With Colonic Intraepithelial Lymphocytosis Refractory To Budesonide Treatment - A Case Report. (PubMed, Z Gastroenterol) - "Advanced therapies including anti-TNF-alpha (e.g. infliximab) or anti-integrin (e.g. vedolizumab) agents as well as JAK inhibitors (e.g. upadacitinib) may be considered in refractory cases. Here, we present the case of a 78-year-old female patient with a twenty month history of chronic refractory diarrhea, repeatedly diagnosed as microscopic lymphocytic colitis. Following further deterioration and the development of hepatosplenomegaly with atypical liver lesions, a review of colonic biopsies and additional work-up led to the correct diagnosis."

Journal • Gastroenterology • Gastrointestinal Disorder • Hepatology • Immunology • Oncology

Analysis of Onset Timing and Risk Factors for Mesalazine-related Adverse Events Using the JADER Database. (PubMed, In Vivo) - "Most mesalazine-associated AEs occurred shortly after treatment initiation, although some manifested later. Although direct risk quantification could not be performed from individual RORs, the indicated factors associated with mesalazine intolerance-including sex and specific concomitant drugs might be useful as items for monitoring AEs. These findings provide meaningful insights that may contribute to optimizing therapeutic strategies and improving the quality of life of patients with IBD."

Adverse events • Journal • Cardiovascular • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Interstitial Lung Disease • Pulmonary Disease • Respiratory Diseases

Pneumococcal Vaccine Is Associated with Improved Outcomes in Inflammatory Bowel Disease: Insights from a Propensity-Matched Study in the United States. (PubMed, Dig Dis Sci) - "These findings align with current recommendations supporting pneumococcal vaccination in adult patients with IBD and highlight the importance of further studies to clarify the extent of vaccine-related benefit in this population."

Journal • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Pneumococcal Infections • Pneumonia • Preventive care • Respiratory Diseases

Mechanisms of cellular senescence combined with molecular docking strategies: A biomarker study of potential therapeutic targets for allergic rhinitis. (PubMed, PLoS One) - "Mining AR-related Hub senescence genes by bioinformatics analysis, constructing PPI network, ceRNA network, transcription factor regulatory network, gene-drug interaction network and molecular docking validation, we screened 19 CCL2, STAT1, TLR2, IGFBP3, TLR3, KLF4, IL1RN, IRF1, SERPINB2, DPP4, MME, NQO1, SAMHD1, XAF1, PHGDH, EIF4EBP1, CTH, HSPA2, and AHR are expected to be Hub genes for potential diagnostic and therapeutic biomarkers, which will provide targets and new insights for further in-depth explorations of AR cellular senescence-related mechanisms of action and therapy."

Biomarker • Journal • Allergic Rhinitis • Immunology • Inflammation • CCL2 • EIF4EBP1 • IGFBP3 • IL1RN • IRF1 • KLF4 • NQO1 • PHGDH • STAT1 • TLR2 • TLR3 • XAF1